Zuranolone for Postpartum Depression: Results from the SKYLARK Study
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
Essential Reads: Zuranolone for Postpartum Depression
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]